Showing 2881-2890 of 5621 results for "".
- Bausch + Lomb Initiates Clinical Trial Evaluating New Ophthalmic Viscosurgical Devicehttps://modernod.com/news/bausch-lomb-initiates-clinical-trial-evaluating-new-ophthalmic-viscosurgical-device/2480163/Bausch + Lomb announced that it has initiated a clinical trial evaluating the safety and efficacy of a new ophthalmic viscosurgical device (OVD). Bausch + Lomb aims to file for premarket approval (PMA) with the FDA at the conclusion of the clinical trial, with plans to bring this next-generation
- LayerBio Awarded $1.2 Million from NIH to Develop Sustained-Release Glaucoma Drughttps://modernod.com/news/layerbio-awarded-1-2-million-from-nih-to-develop-sustained-release-glaucoma-drug/2480164/Founded in 2013 as a spin-off from the lab of Dr. Paula Hammond at MIT, LayerBio is developing novel drug delivery products for ophthalmology, wound care, tendon repair and other unmet medical needs. The National Eye Institute at the National I
- Takeda Reaches Deal to Buy Shire for $62 Billionhttps://modernod.com/news/takeda-reaches-deal-to-buy-shire-for-around-62-billion/2480166/After several failed attempts, Japanese drugmaker Takeda Pharmaceutical managed to reach an agreement to acquire Shire in a $62 billion deal. The offer is approximately 46 percent cash and 54 percent stock, leaving Shire shareholders owning around half of the combined group. Shire investors will
- Takeda Nears Deal to Buy Shire in Its Biggest Purchasehttps://modernod.com/news/takeda-nears-deal-to-buy-shire-in-its-biggest-purchase/2480167/Takeda Pharmaceutical is nearing an agreement to buy rival drugmaker Shire, people familiar with the matter said, according to a report in Bloomberg. The deal, if appr
- Hoya Achieves CE Mark for 4-in-1 Multisert Preloaded Delivery System with Vivinex IOLhttps://modernod.com/news/hoya-achieves-ce-mark-for-4-in-1-multisert-preloaded-delivery-system-with-vivinex-iol/2480171/Hoya Surgical Optics has obtained European CE Mark for the Vivinex IOL with the new multiSert 4-in-1 preloaded delivery system. MultiSert offers cataract surgeons control in the palm of their hands as they now have the option of using either a two-handed screw or a one-handed technique while impl
- Optos Unveils Monaco Ultra-Widefield Imaging Device with OCT Capabilitieshttps://modernod.com/news/optos-unveils-monaco-ultra-widefield-imaging-device-with-oct-capabilities/2480175/Optos has announced that Monaco, which the company describes as the first ultra-widefield imaging device combined with OCT, was launched Thursday in the United States. Monaco is a compact desk-top UWF retinal imaging device that provides greater imaging functionality and expands the compan
- Visulytix’s AI Tool Equivalent to Human Experts in Glaucoma Detectionhttps://modernod.com/news/visulytixs-ai-tool-equivalent-to-human-experts-in-glaucoma-detection/2480181/Visulytix announced that Pegasus-disc, its artificial intelligence (AI) decision support tool for the analysis of retinal images, has been shown to perform similarly to the consensus opinion of human experts when detecting glaucoma from optic disc images. This follows a study conducted on the ima
- Avedro Announces $25 Million in Funding to Fuel Innovation and Commercial Growthhttps://modernod.com/news/avedro-announces-25-million-in-funding-to-fuel-innovation-and-commercial-growth/2480188/Avedro announced that it has secured $25 million in financing to invest in product development, clinical studies and commercial efforts, including expansion of sales and reimbursement support. “Avedro’s mission is to develop noninvasive corneal remodeling treatments that protect and improv
- New Novartis Phase 3 Data for Brolucizumab Demonstrate Reliability of 12-Week Treatment Intervalhttps://modernod.com/news/new-novartis-phase-3-data-for-brolucizumab-demonstrate-reliability-of-12-week-treatment-interval/2480190/Novartis announced new positive brolucizumab (RTH258) data in neovascular age-related macular degeneration (AMD) from a prespecified secondary analysis of the phase 3 HAWK and HARRIER trials. The findings showed that patients assessed as appropriate for a 12-week treatment frequency during
- Allergan CEO: Large Deal Would Be An Unlikely Outcome of Reviewhttps://modernod.com/news/allergan-ceo-large-deal-would-be-an-unlikely-outcome-of-review/2480196/Allergan Chief Executive Brent Saunders said on Monday that while the company is considering large, transformational deals as part of a strategic review, they are a “very low priority and a very unlikely outcome” of the process, according to a Reuters